– USA, CA – Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the appointment of veteran pharmaceutical industry executive Dr. Oye Olukotun, M.D., MPH, to its Board as an independent director, effective September 1st, 2020.
“Oye is a senior physician executive, with deep scientific and clinical development experience across broad markets. His extensive and proven track record in successfully developing products through approval, particularly with cardiometabolic products, will be of tremendous value to Arrowhead as the company advances its two important cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, into later stage development and continues to expand its broad pipeline.” said Board Chairman, Dr. Douglass Given.
About Dr. Oye Olukotun
Oye Olukotun is a Mayo Clinic trained Cardiologist who currently serves as the CEO of CR Strategies, LLC. He served as the CEO of Epigen Pharmaceuticals, Inc. from 2014 to 2017, and Vice-Chairman of CardioVax, Inc., from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta-blocker and the first approved ACE inhibitor, among others.
Dr. Olukotun currently serves on the board of directors for Tonix Pharmaceuticals Holding Corp.
“I’m thrilled to join the Board of Arrowhead Pharmaceuticals,” said Dr. Olukotun. “Arrowhead has an exciting pipeline of truly meaningful products and I’m excited to help the company demonstrate their value.”
Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information: https://arrowheadpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
